AbbVie (NYSE:ABBV) Shares Down 2.1% – Should You Sell?

AbbVie Inc. (NYSE:ABBV) shares were down 2.1% during mid-day trading on Monday. The stock traded as low as $286.14 and last traded at $288.6560. Approximately 8,834,601 shares changed hands during mid-day trading, an increase of 39% from the average daily volume of 6,341,916 shares. The stock had previously closed at $294.89.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals signed a global license agreement to develop next-generation migraine therapies. The deal could be worth up to approximately $757 million, adding another potential growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
• Positive Sentiment: Positive Phase 3 migraine results: AbbVie reported a Phase 3 study win published in The Lancet Neurology, supporting the potential of its migraine treatment portfolio and strengthening its neuroscience growth outlook. AbbVie Lands Phase 3 Migraine Study Win
• Positive Sentiment: Analysts raised price targets: Cantor Fitzgerald increased its target to $325, RBC to $330, Canaccord Genuity to $338, Leerink Partners to $342 and Morgan Stanley to $346. The upgrades followed AbbVie’s stronger-than-expected third-quarter results and improved outlook. Analysts Increase Their Forecasts on AbbVie
• Positive Sentiment: Growth transition remains on track: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products offset Humira’s decline, and AbbVie raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
• Positive Sentiment: Dividend increased: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, or $7.28 annually, reinforcing its appeal to income-focused investors.
• Neutral Sentiment: Legal win over drug pricing: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug price controls. The ruling may preserve pricing flexibility, although the longer-term regulatory outlook remains uncertain. AbbVie Wins Drug Price Control Lawsuit
• Negative Sentiment: Valuation and transition concerns: Although Skyrizi and Rinvoq are replacing Humira revenue, investors remain focused on whether AbbVie’s newer growth engines can sustain momentum as Humira fades. The stock’s recent rally and high valuation may also be encouraging short-term profit-taking.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. The Goldman Sachs Group raised their target price on shares of AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. BMO Capital Markets raised their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Citigroup lifted their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Barclays boosted their target price on AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $293.29.

AbbVie Trading Down 2.1%

The firm has a market capitalization of $510.00 billion, a PE ratio of 49.68, a PEG ratio of 1.35 and a beta of 0.24. The firm’s fifty day moving average price is $269.35 and its 200 day moving average price is $237.23.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The firm had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the firm earned $1.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts expect that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its position in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP acquired a new stake in AbbVie in the 2nd quarter valued at approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new position in AbbVie during the second quarter valued at approximately $2,905,952,000. Finally, Deutsche Bank AG grew its stake in shares of AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.